Fundraising FoxEcoR1 Capital — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Board seatOleg Nodelman· per SEC Form D
Co-investorsAndreessen HorowitzMPM BioImpactMRL Ventures FundPappas CapitalRA CapitalTCG Crossover+5 more
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)
Co-investorsARCH Venture PartnersF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship PioneeringFlagship Ventures
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesForesite CapitalNat TurnerNextech InvestSoftBank Vision FundCurie.Bio+2 more
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)
Board seatOleg Nodelman· per SEC Form D
Co-investorsAtlas VentureAvoro Capital AdvisorsFrazier Life SciencesNextech InvestVida VenturesAbingworth+3 more
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesGV (Google Ventures)The Column GroupAbbVieJJDC+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.